OptiNose

OptiNose — Q3 2023 Earnings Presentation

22 slides from OptiNose's earnings presentation, Nov 9, 2023

  1. Slide 1: Building a Leading ENT / Allergy Specialty Company

    Building a Leading ENT / Allergy Specialty Company C o r p o r a t e P r e s e n t a t i o n N o v e m b e r 9 , 2 0 2 3 Exhibit 99.2

  2. Slide 2: Forward-Looking Statements

    2 Forward-Looking Statements This presentation and our accompanying remarks contain “forward-looking statements” within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. All statements that are not historical facts are hereby identified as forward-looking statements for this

  3. Slide 3: Key Takeaways

    3 Key Takeaways Chronic sinusitis is a 10-fold market opportunity for XHANCE Executing our strategy to prioritize the potential launch of XHANCE as the first-ever FDA approved drug treatment for CS sNDA target action date in December 2023

  4. Slide 4: XHANCE as First FDA-approved Drug Treatment for Chronic Sinusitis Would Create Growth Opportunities

    4 Successful Development of XHANCE as the First and Only FDA-approved Drug Treatment for Chronic Sinusitis Would Create Multiple New Growth Opportunities Up to ~1 Million patients with nasal polyps (NP) are treated by specialty physicians in our current sales deployment $1B TAM $3B TAM Up to ~10 Mil

  5. Slide 5: ReOpen Program Update

    optinose_ ——— ReOpen Program Update

  6. Slide 6: CS Supplemental NDA - Anticipated Next Steps

    6 CS Supplemental NDA - Anticipated Next Steps  FDA accepted for review our supplemental new drug application (sNDA) in pursuit of a new indication  PDUFA target action date is December 16, 2023 - Standard review period was applied

  7. Slide 7: Q3 2023 Performance

    optinose_ ——— Q3 2023 Performance

  8. Slide 8: XHANCE Prescriptions – Third Quarter 2023

    8 XHANCE Prescriptions – Third Quarter 2023 Overall XHANCE New Prescriptions decreased 4% and Total Prescriptions decreased 6% HCPs who had a prescription filled by their patients increased 5% from Q3 2022 to Q3 2023 28.6 27.4 Q3 '22 Q3 '23 (in thousands) XHANCE New Prescriptions 89.9 84.1 Q3 '22 Q3

  9. Slide 9: Q3 2023 Financial Update

    optinose_ —— Q3 2023 Financial Update

  10. Slide 10: Financial Review – Third Quarter 2023

    10 Financial Review – Third Quarter 2023 SG&A plus R&D expenses decreased by ~$9 million from Q3 2022 to Q3 2023 and Q3 2023 XHANCE Net Revenues of $19.8 million supported an increase to FY 2023 expectations $28.8 $19.3 Q3 '22 Q3 '23 ($M) SG&A plus R&D Expenses $20.1 $19.8 Q3 '22 Q3 '23 ($M) Net Rev

  11. Slide 11: 2023 Outlook

    optinose_ ——— 2023 Outlook

  12. Slide 12: Full Year 2023 Financial Guidance

    12 Full Year 2023 Financial Guidance  XHANCE Net Revenue ‒ FY 2023 expected to be between $66 to $70 million ‒ Previously expected to be between $64 to $70 million ‒ FY 2023 expectation does not include net revenues from a CS launch  XHANCE Average Net Revenue per Prescription ‒ FY 2023 expected t

  13. Slide 13: Closing Remarks

    optinose_ ——— Closing Remarks

  14. Slide 14: Key Takeaways

    14 Key Takeaways Chronic sinusitis is a 10-fold market opportunity for XHANCE Executing our strategy to prioritize the potential launch of XHANCE as the first-ever FDA approved drug treatment for CS sNDA target action date in December 2023

  15. Slide 15: Investor Relations – Optinose Investor Contact

    15 Investor Relations – NASDAQ: OPTN Optinose Investor Contact Jonathan Neely, VP, Investor Relations and Business Development 267-521-0531 Investors@optinose.com As of September 30, 2023: – $66.8 million in cash – Debt: $130 million – 112 million common shares o/s – 45 million options, warrants & R

  16. Slide 16: Appendix - ReOpen Program Co-Primary Endpoints

    Appendix - ReOpen Program Co-Primary Endpoints

  17. Slide 17: Combined Symptom Score (Co-Primary Endpoint)

    17 Combined Symptom Score (Co-Primary Endpoint) Improvement in combined symptoms with XHANCE; Consistent with NAVIGATE I and II 1 -0.81 -1.54* -1.74‡ -2.0 -1.8 -1.6 -1.4 -1.2 -1.0 -0.8 -0.6 -0.4 -0.2 0.0 CS S Po in t R ed uc tio n LS Mean Change in CSS from Baseline to Week 4 EDS-placebo BID OPN-375

  18. Slide 18: Average of Percentages of Opacified Volume (Ethmoid and Maxillary)

    18 Average of Percentages of Opacified Volume (Ethmoid and Maxillary) Objective Evidence of Effect in Sinus Cavities by CT Scan; Co-Primary Endpoint 1.19 -7.00‡ -5.14♰ -8 -7 -6 -5 -4 -3 -2 -1 0 1 2 Pe rc en t R ed uc tio n LS Mean Change in APOV of the Ethmoid and Maxillary Sinuses from Baseline to

  19. Slide 19: Appendix – Year to Date Prescription and Financial Results

    Appendix – Year to Date Prescription and Financial Results

  20. Slide 20: XHANCE Prescriptions – YTD September 2023

    20 XHANCE Prescriptions – YTD September 2023 XHANCE New Prescriptions increased 1% and Total Prescriptions increased 1% 88.2 88.8 YTD Sep '22 YTD Sep '23 (in thousands) XHANCE New Prescriptions 258.5 260.0 YTD Sep '22 YTD Sep '23 XHANCE Total Prescriptions (in thousands) Estimated based on monthly p

  21. Slide 21: Financial Review – YTD September 2023

    21 Financial Review – YTD September 2023 YTD 2023 SG&A plus R&D expenses decreased by ~$32 million compared to YTD 2023 and YTD 2023 XHANCE Net Revenues of $51.1 million are greater than initially expected $96.7 $64.9 YTD Sep '22 YTD Sep '23 ($M) SG&A plus R&D Expenses $55.4 $51.1 0 10 20 30 40 50 6

  22. Slide 22: Building a Leading ENT / Allergy Specialty Company

    Building a Leading ENT / Allergy Specialty Company C o r p o r a t e P r e s e n t a t i o n N o v e m b e r 9 , 2 0 2 3

OptiNose — Q3 2023 Earnings Presentation on 6ix